Full Description
| Cataloguing Source | LibUI ind rda |
| Content Type | text (rdacontent) |
| Media Type | unmediated (rdamedia); computer (rdamedia) |
| Carrier Type | volume (rdacarrier); online resource (rdacarrier) |
| Physical Description | xvii, 112 pages ; 28 cm + appendix |
| Concise Text | |
| Holding Institution | Universitas Indonesia |
| Location | Perpustakaan UI, Lantai 3 |
- Availability
- Digital Files: 1
- Review
- Cover
- Abstract
| Call Number | Barcode Number | Availability |
|---|---|---|
| T39231 | 15-23-67988218 | TERSEDIA |
| No review available for this collection: 20365481 |
Abstract
ABSTRAK
Tablet lepas lambat merupakan tablet yang di desain untuk melepaskan obat secara perlahan ? lahan di dalam saluran cerna, dengan menggunakan matriks sebagai salah satu komponen utama. Penelitian ini bertujuan untuk memperoleh eksipien koproses xanthan gum ? amilosa tersambungsilang (Ko-CLA6-XG dan Ko-CLA12-XG); (CL6-Ko-A-XG dan CL12-Ko-A-XG) sebagai matriks tablet lepas lambat natrium diklofenak. Eksipien Ko-CLA6-XG dan Ko-CLA12-XG merupakan hasil koproses xanthan gum dengan CLA6 dan xanthan gum dengan CLA12. Eksipien CL6-Ko-A-XG dan CL12-Ko-A-XG dihasilkan dengan cara sambungsilang dari hasil koproses xanthan gum dan amilosa menggunakan natrium trimetafosfat dengan perbandingan masing ? masing eksipien yaitu 1:1, 1:2 dan 2:1. Ko-CLA6-XG, Ko-CLA12-XG, CL6-Ko-A-XG dan CL12-Ko-A-XG yang dihasilkan dikarakterisasi sifat fisik, kimia dan fungsional. Ko-CLA6-XG dan Ko-CLA12-XG mempunyai derajat substitusi 0,070 dan 0,110. Eksipien CL6- Ko-A-XG 1:1, 1:2 dan 2:1 berturut ? turut 0,077; 0,081 dan 0,083 serta CL12-Ko- A-XG 1:1, 1:2 dan 2:1 berturut ? turut 0,113; 0,119 dan 0,122. Eksipien tersebut mempunyai kemampuan mengembang yang baik, viskositas yang cukup besar dan kekuatan gel yang baik. Tablet dengan matriks Ko-CLA6-XG, Ko-CLA12-XG, CL6-Ko-A-XG dan CL12-Ko-A-XG diformulasikan dengan metode cetak langsung dan seluruhnya memenuhi persyaratan evaluasi tablet. Profil pelepasan natrium diklofenak dari tablet yang mengandung matriks Ko-CLA6-XG (F1 ? F3), Ko-CLA12-XG (F4 ? F6), CL6-Ko-A-XG (F7 ? F9) dan CL12-Ko-A-XG (F10 ? F12) dalam medium dapar fosfat selama 8 jam, menunjukkan profil pelepasan obat diperlambat dengan kinetika pelepasan orde nol (F1 ? F6, F9, F11) dan Korsmeyer-Peppas (F7, F8, F10, F12). Oleh karena itu, F1 ? F6 dapat digunakan untuk sediaan lepas lambat selama 16 jam sedangkan F7 ? F12 dapat digunakan untuk sediaan lepas lambat selama 32 jam.
ABSTRACT
Sustained release tablet was solid dosage form which was designed to release drugs slowly in gastrointestinal tract. This present research was intended to produce coprocessed excipient of xanthan gum-crosslinked amylose (Co-CLA6- XG and Co-CLA12-XG); (CL6-Co-A-XG and CL12-Co-A-XG) as matrix for sustained release tablet of sodium diclofenac. Co-CLA6-XG and Co-CLA12-XG were produced by coprocessing xanthan gum with CLA6 and xanthan gum with CLA12. CL6-Co-A-XG and CL12-Co-A-XG were produced from the coprocessed xanthan gum and amylose then were crosslinked with sodium trimethaphosphate. All excipient had a ratio 1:1, 1:2 and 2:1. The obtained Co- CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG were characterized physically, chemically and functionally. The degree of substitution (DS) of Co-CLA6-XG and Co-CLA12-XG were 0,070 and 0,110. Then the DS of CL6-Co-A-XG 1:1, 1:2 and 2:1 were respectively 0,077; 0,081 and 0,083. The DS of CL12-Co-A-XG 1:1, 1:2 and 2:1 were respectively 0,113; 0,119 and 0,122. All excipients had good swelling index, high viscosity and good gel strenght. Tablets with Co-CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG matrix were formulated by direct compression method and passed tablet evaluation tests. The release profile of sodium diclofenac which contained matrix from Co-CLA6- XG (F1 ? F3), Co-CLA12-XG (F4 ? F6), CL6-Co-A-XG (F7 ? F9) and CL12-Co- A-XG (F10 ? F12) in phospate buffer medium for 8 hours, showed that the sustained release profile followed zero order kinetics (F1 ? F6, F9, F11) and Korsmeyer-Peppas (F7, F8, F10, F12). Thus, F1 ? F6 tablet formulations could be applied as sustained release tablet formulas and could retard drug release up to 16 hours. Then F7 ? F12 could be applied as sustained release tablet formula and could retard drug release up to 32 hours.
Tablet lepas lambat merupakan tablet yang di desain untuk melepaskan obat secara perlahan ? lahan di dalam saluran cerna, dengan menggunakan matriks sebagai salah satu komponen utama. Penelitian ini bertujuan untuk memperoleh eksipien koproses xanthan gum ? amilosa tersambungsilang (Ko-CLA6-XG dan Ko-CLA12-XG); (CL6-Ko-A-XG dan CL12-Ko-A-XG) sebagai matriks tablet lepas lambat natrium diklofenak. Eksipien Ko-CLA6-XG dan Ko-CLA12-XG merupakan hasil koproses xanthan gum dengan CLA6 dan xanthan gum dengan CLA12. Eksipien CL6-Ko-A-XG dan CL12-Ko-A-XG dihasilkan dengan cara sambungsilang dari hasil koproses xanthan gum dan amilosa menggunakan natrium trimetafosfat dengan perbandingan masing ? masing eksipien yaitu 1:1, 1:2 dan 2:1. Ko-CLA6-XG, Ko-CLA12-XG, CL6-Ko-A-XG dan CL12-Ko-A-XG yang dihasilkan dikarakterisasi sifat fisik, kimia dan fungsional. Ko-CLA6-XG dan Ko-CLA12-XG mempunyai derajat substitusi 0,070 dan 0,110. Eksipien CL6- Ko-A-XG 1:1, 1:2 dan 2:1 berturut ? turut 0,077; 0,081 dan 0,083 serta CL12-Ko- A-XG 1:1, 1:2 dan 2:1 berturut ? turut 0,113; 0,119 dan 0,122. Eksipien tersebut mempunyai kemampuan mengembang yang baik, viskositas yang cukup besar dan kekuatan gel yang baik. Tablet dengan matriks Ko-CLA6-XG, Ko-CLA12-XG, CL6-Ko-A-XG dan CL12-Ko-A-XG diformulasikan dengan metode cetak langsung dan seluruhnya memenuhi persyaratan evaluasi tablet. Profil pelepasan natrium diklofenak dari tablet yang mengandung matriks Ko-CLA6-XG (F1 ? F3), Ko-CLA12-XG (F4 ? F6), CL6-Ko-A-XG (F7 ? F9) dan CL12-Ko-A-XG (F10 ? F12) dalam medium dapar fosfat selama 8 jam, menunjukkan profil pelepasan obat diperlambat dengan kinetika pelepasan orde nol (F1 ? F6, F9, F11) dan Korsmeyer-Peppas (F7, F8, F10, F12). Oleh karena itu, F1 ? F6 dapat digunakan untuk sediaan lepas lambat selama 16 jam sedangkan F7 ? F12 dapat digunakan untuk sediaan lepas lambat selama 32 jam.
ABSTRACT
Sustained release tablet was solid dosage form which was designed to release drugs slowly in gastrointestinal tract. This present research was intended to produce coprocessed excipient of xanthan gum-crosslinked amylose (Co-CLA6- XG and Co-CLA12-XG); (CL6-Co-A-XG and CL12-Co-A-XG) as matrix for sustained release tablet of sodium diclofenac. Co-CLA6-XG and Co-CLA12-XG were produced by coprocessing xanthan gum with CLA6 and xanthan gum with CLA12. CL6-Co-A-XG and CL12-Co-A-XG were produced from the coprocessed xanthan gum and amylose then were crosslinked with sodium trimethaphosphate. All excipient had a ratio 1:1, 1:2 and 2:1. The obtained Co- CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG were characterized physically, chemically and functionally. The degree of substitution (DS) of Co-CLA6-XG and Co-CLA12-XG were 0,070 and 0,110. Then the DS of CL6-Co-A-XG 1:1, 1:2 and 2:1 were respectively 0,077; 0,081 and 0,083. The DS of CL12-Co-A-XG 1:1, 1:2 and 2:1 were respectively 0,113; 0,119 and 0,122. All excipients had good swelling index, high viscosity and good gel strenght. Tablets with Co-CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG matrix were formulated by direct compression method and passed tablet evaluation tests. The release profile of sodium diclofenac which contained matrix from Co-CLA6- XG (F1 ? F3), Co-CLA12-XG (F4 ? F6), CL6-Co-A-XG (F7 ? F9) and CL12-Co- A-XG (F10 ? F12) in phospate buffer medium for 8 hours, showed that the sustained release profile followed zero order kinetics (F1 ? F6, F9, F11) and Korsmeyer-Peppas (F7, F8, F10, F12). Thus, F1 ? F6 tablet formulations could be applied as sustained release tablet formulas and could retard drug release up to 16 hours. Then F7 ? F12 could be applied as sustained release tablet formula and could retard drug release up to 32 hours.